Alzheimer’s & Dementia Care
-
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel, first-in-class treatment specifically targeting…
Read More » -
Daily Alzheimer’s pill slows brain shrinkage, boosts cognition
New analysis presented by Anavex Life Sciences indicates that the therapeutic benefits observed in individuals with early-stage Alzheimer’s disease after…
Read More » -
U.S. FDA Approves Leqembi Iqlik Subcutaneous Autoinjector for Early Alzheimer’s Disease Maintenance Dosing
The U.S. Food and Drug Administration (FDA) has announced the approval of Leqembi Iqlik (lecanemab-irmb), an innovative under-the-skin autoinjector formulation…
Read More » -
The Relentless Unraveling: Navigating the Complexities of Alzheimer’s Disease
Alzheimer’s disease is often described as a long farewell—a relentless unraveling of memory, identity, and connection, presenting a profound and…
Read More » -
Kisunla approval offers new option for early Alzheimer’s in Europe
The European Commission has granted marketing authorization for Eli Lilly’s monthly infusion therapy, Kisunla (donanemab), targeting adults with early symptomatic…
Read More » -
Health Canada Conditionally Approves Leqembi, Marking a Pivotal Shift in Alzheimer’s Treatment by Targeting Underlying Disease Cause
Health Canada has granted conditional approval for Leqembi (lecanemab), a groundbreaking therapy co-developed by Eisai and Biogen, for specific adults…
Read More » -
Semaglutide Fails to Slow Alzheimer’s Progression in Pivotal Phase 3 Trials, Halting Further Development for the Condition.
Semaglutide, an anti-diabetic medication widely known under brand names like Ozempic, Rybelsus, and Wegovy, did not demonstrate a statistically significant…
Read More » -
Blarcamesine Demonstrates Sustained Efficacy Over Three Years in Early Alzheimer’s Disease, Offering Hope for Disease Modification
Copenhagen, Denmark – In a significant development for Alzheimer’s disease research, Anavex Life Sciences has announced that the therapeutic benefits…
Read More » -
FDA Grants Priority Review to Axsome Therapeutics’ AXS-05 for Alzheimer’s Agitation, Accelerating Potential Approval for a Critical Unmet Need
The U.S. Food and Drug Administration (FDA) has granted priority review to Axsome Therapeutics’ supplemental New Drug Application (sNDA) for…
Read More » -
FDA Reviews Expanded Approval for Leqembi Iqlik: Subcutaneous Option for Early Alzheimer’s Treatment Initiation
The U.S. Food and Drug Administration (FDA) is currently reviewing a supplemental Biologics License Application (sBLA) seeking expanded approval for…
Read More »
